Articles dans des revues avec comité de lecture (396)
  1. 73. Cortes, J., Rugo, H. H., Awada, A., Twelves, C., Perez, E. A., Im, S. –., Gómez-Pardo, P., Schwartzberg, L. L., Diéras, V., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., & O’Shaughnessy, J. (2017). Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7). Breast cancer research and treatment, 165(2), 329-341. doi:10.1007/s10549-017-4482-3
  2. 74. Cortes, J., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., O'Shaughnessy, J., Rugo, H., Awada, A., Twelves, C., Perez, E. A., Im, S. A., Gómez-Pardo, P., Schwartzberg, L. L., & Diéras, V. (2017). Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast cancer research and treatment, 165(2), 329-341. doi:10.1007/s10549-017-4304-7
  3. 75. Lambertini, M., Goldrat, O., Clatot, F., Demeestere, I., & Awada, A. (2017). Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Current opinion in oncology, 29(4), 243-252. doi:10.1097/CCO.0000000000000380
  4. 76. Baselga, J., Ito, Y., Awada, A., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L. M., Hurvitz, S., Masuda, N., Takahashi, M., Vuylsteke, P., Im, S. A., Hachemi, S., Dharan, B., Di Tomaso, E., Urban, P., Massacesi, C., Campone, M., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., Arteaga, C. C., Jonat, W., & Clemons, M. J. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 18(7), 904-916. doi:10.1016/S1470-2045(17)30376-5
  5. 77. El Hachem, G., Jungels, C., De Saint Aubain, N., Awada, A., & Gil, T. (2017). Extra-osseous Ewing sarcoma of the thyroid gland mimicking a hemorrhagic cyst of Hashimoto thyroiditis. Journal of clinical review & case reports, 2(1), 1-3.
  6. 78. Baselga, J., Haddad, T., Ciruelos Gil, E. M., Vuylsteke, P., Ebbinghaus, S., Im, E., Eaton, L., Pathiraja, K., Gause, C., Mauro, D., Jones, M. B., Morales, S., Rugo, H., Awada, A., Blum, J. J., Tan, A. R., Ewertz, M., Cortes, J., Moy, B., & Ruddy, K. K. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast cancer research and treatment, 163(3), 535-544. doi:10.1007/s10549-017-4199-3
  7. 79. Kourie Hampig, R., Awada, G., & Awada, A. (2017). The second wave of immune checkpoint inhibitor tsunami: Advance, challenges and perspectives. Immunotherapy, 9(8), 647-657. doi:10.2217/imt-2017-0029
  8. 80. Twelves, C., Yardley, D., Potter, D. D., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L., Rugo, H., Cortes, J., O'Shaughnessy, J., Awada, A., Perez, E. A., Im, S. A., Gómez-Pardo, P., Schwartzberg, L. L., & Diéras, V. (2017). Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. European journal of cancer, 76, 205-215. doi:10.1016/j.ejca.2017.02.011
  9. 81. Kourie Hampig, R., Kanaan, H., Awada, G., & Awada, A. (2017). Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. Future oncology, 13(12), 1097-1103. doi:10.2217/fon-2016-0494
  10. 82. Solinas, C., Chanzá, N. M., Awada, A., & Scartozzi, M. (2017). The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer treatment reviews, 53, 138-145. doi:10.1016/j.ctrv.2016.12.004
  11. 83. Specenier, P. M., Menis, J., Vermorken, J. B., Remenar, E., Buter, J., Schrijvers, D., Bergamini, C., Licitra, L., Awada, A., Clement, P. M. J. P., & Fortpied, C. (2017). TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: A randomized phase II EORTC trial. Annals of oncology, 28(9), 2219-2224. doi:10.1093/annonc/mdx300
  12. 84. Psyrri, A., Remenar, E., Degardin, M., Pateras, I. I., Langendijk, J. J., van Herpen, C. C., Awada, A., Germa, J. R. L. J., Kienzer, H. R., Licitra, L., Vermorken, J. B., Fortpied, C., Koutsodontis, G., Avgeris, M., Kroupis, C., Goutas, N., Menis, J., Herman, L., & Giurgea, L. (2017). Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study. Annals of oncology, 28(9), 2213-2218. doi:10.1093/annonc/mdx320
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>